LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

Fabrice André, Jorge Nadal, Hannelore Denys, Shom Goel, L.M. Litchfield, A. Appiah, Yongmei Chen, Sara M. Tolaney